LOVALTECH

Lovaltech is a French biotech company pioneering next-generation nasal vaccines for infectious diseases. Spun out from cutting-edge academic research at INRAE and the University of Tours, Lovaltech develops needle-free vaccine solutions with enhanced mucosal immunity, better protection at the entry site of pathogens, and potential for both prevention and therapy.​ ​

LVT-001 is a novel nasal COVID-19 vaccine targeting current and future variants. Designed to induce strong mucosal and systemic immune responses, LVT-001 has demonstrated a broad protection across variants, Sterilizing immunity and safe abs scalable production using fusion proteins abd GRAS-grade excipients. They launched their first-in-human clinical trials with regulatory engagement underway via the European Medicines Agency (EMA).​ ​ And they are already developing the next vaccine candidates against Covid-Long, Influenza and Malaria.​ ​

Finaly, Lovaltech set-up a tech platform of Modular Muco-Excipient (ME) Platform: A Breakthrough Innovation for Nasal Vaccination.